Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 9;22(9):999–1012. doi: 10.1158/1535-7163.MCT-22-0786

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. XMT-1660 activity in ovarian tumors and PD-1 refractory breast tumor. A, Antitumor activity of XMT-1660 in OV2423 ovarian cancer PDX. Inset, B7-H4 IHC. B, Antitumor activity of XMT-1660 in CTG-1692 ovarian cancer PDX. Inset, B7-H4 IHC. C, Antitumor activity of XMT-1660 in mBR9013 MMTV-ERBB2-derived syngeneic tumor in FVB/NJ. Anti–PD-1 immune checkpoint inhibitor was also evaluated (dosed BIWx3 (IP)). Inset, B7-H4 (top) and PD-L1 (bottom) IHC. — XMT-1660 activity in ovarian tumors and PD-1 refractory breast tumor. A, Antitumor activity of XMT-1660 in OV2423 ovarian cancer PDX. Inset, B7-H4 IHC. B, Antitumor activity of XMT-1660 in CTG-1692 ovarian cancer PDX. Inset, B7-H4 IHC. C, Antitumor activity of XMT-1660 in mBR9013 MMTV-ERBB2-derived syngeneic tumor in FVB/NJ. Anti–PD-1 immune checkpoint inhibitor was also evaluated (dosed BIWx3 (IP)). Inset, B7-H4 (top) and PD-L1 (bottom) IHC.